Year: 2020
Type: article
Study designs: Systematic Review, Meta-Analysis
Abstract: T he incidence of coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has spread rapidly globally; as of March 29, 2020, ≈670,000 cases had been confirmed worldwide (1).COVID-19 is typically a pulmonary infection that can range from mild illness to acute respiratory distress syndrome and multiple organ failure; however, other symptoms such as myalgias and anorexia have been noted (2).Although many ongoing studies are investigating measurement of proinflammatory cytokines and other biomarkers as a way to prognosticate infection severity, we investigated use of 2 easily obtained predictors: lymphopenia and leukocytosis (3). The StudyWe searched 3 major databases-MEDLINE/ PubMed, EMBASE, and CENTRAL (Cochrane Central Register of Controlled Trials)-for clinical studies published December 1, 2019, through March 28, 2020.To broadly identify studies detailing lymphocyte and leukocyte testing among patients with COVID-19, we used the following search criteria: "(COVID-19 OR SARS-CoV-2 OR 2019-NCoV OR HCov-19 OR novel coronavirus) AND (laboratory OR WBC OR lymphocyte)."We prioritized studies that measured lymphocyte and leukocyte counts among patients who had severe or critical cases versus those with mild cases.Severe cases were defined as significant respiratory distress (acute hypoxic respiratory failure, acute respiratory distress syndrome, need for mechanical ventilation, or intensive care unit admission) caused by COVID-19.Our meta-analysis included articles about studies and clinical trials that met the following 4 inclusion criteria: 1) involved adult, human patients; 2) written in English; 3) reported lymphocyte and leukocyte counts for patients; and 4) compared patients with severe versus mild illness.Our meta-analysis excluded articles about studies with the following 9 characteristics: 1) involved nonhuman subjects; 2) written in a language other than English; 3) were not a clinical trial, such as a review paper or letter; 4) were out of the scope of the study question detailed above; 5) did not provide raw data to perform quantitative metaanalysis; 6) involved pediatric patients; 7) did not have the full article available; 8) were duplicates; and 9) were ongoing or not completed.We performed the meta-analysis by using Review Manager software version 5.3 (The Cochrane Collaboration, https://training.cochrane.org).We calculated mean differences (MDs) between groups for continuous variables and reported 95% CIs for both severe and nonsevere cases.If the included studies provided medians and interquartile ranges instead of MDs and SDs, we imputed the MDs and SDs as described previously (4-6) and additionally described in the Cochrane Handbook for Systematic Reviews (7).We considered results statistically insignificant if p>0.05 or if the MD included zero.We assessed statistical heterogeneity by using the I 2 statistic and awarded the following values: 0%-24%, homogeneity; 25%-49%, mild heterogeneity; 50%-74%, moderate heterogeneity; and >75%, high Prognostic Value of Leukocytosis and Lymphopenia for Coronavirus Disease Severity
Source: Emerging infectious diseases
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W3021698968
